Format

Send to

Choose Destination
See comment in PubMed Commons below
J Nucl Med. 2012 Feb;53(2):330-5. doi: 10.2967/jnumed.111.094565. Epub 2012 Jan 12.

Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans.

Author information

1
Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. endres@jhmi.edu

Abstract

Whole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET ligand for the assessment of translocator protein.

METHODS:

Six healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of (11)C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding.

RESULTS:

The absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10(-2) mSv/MBq (7.43 × 10(-2) rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for (11)C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi).

CONCLUSION:

(11)C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other (11)C-labeled PET tracers.

PMID:
22241913
PMCID:
PMC3274766
DOI:
10.2967/jnumed.111.094565
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center